Request Demo
Last update 08 May 2025
Factor VIII (Guangdong Shuanglin Biological Pharmaceutical)
Last update 08 May 2025
Overview
Basic Info
Drug Type Non-recombinant coagulation factor |
Synonyms 人凝血因子VIII (广东双林生物) |
Target |
Action stimulants |
Mechanism F10 stimulants(Coagulation factor X stimulants), Coagulation factor VIII replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (22 Jun 2020), |
RegulationPriority Review (China) |
Login to view timeline
Related
1
Clinical Trials associated with Factor VIII (Guangdong Shuanglin Biological Pharmaceutical)CTR20160129
单臂、开放性、多中心临床试验评价人凝血因子Ⅷ治疗甲型血友病的安全性和有效性
[Translation] A single-arm, open-label, multicenter clinical trial to evaluate the safety and efficacy of human coagulation factor VIII in the treatment of hemophilia A
100 Clinical Results associated with Factor VIII (Guangdong Shuanglin Biological Pharmaceutical)
Login to view more data
100 Translational Medicine associated with Factor VIII (Guangdong Shuanglin Biological Pharmaceutical)
Login to view more data
100 Patents (Medical) associated with Factor VIII (Guangdong Shuanglin Biological Pharmaceutical)
Login to view more data
100 Deals associated with Factor VIII (Guangdong Shuanglin Biological Pharmaceutical)
Login to view more data
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hemophilia A | China | 22 Jun 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free